Education and debate

For and against

Primary angioplasty should be first line treatment for acute myocardial infarctionFOR

BMJ 2004; 328 doi: 10.1136/bmj.328.7450.1254 (Published 20 May 2004)
Cite this as: BMJ 2004;328:1254

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

The UK government is considering establishing a national primary angioplasty service for patients with acute myocardial infarction. David Smith and Kevin Channer debate whether moving away from first line thrombolysis is appropriate or practical

FOR

  1. David Smith, consultant cardiologist (dagobert@eurobell.co.uk)
  1. Royal Devon and Exeter Hospital, Exeter EX2 5DW

    There seems little doubt that acute ST elevation myocardial infarction is the result of coronary arterial occlusion and that myocardial necrosis can be limited by early restoration of normal antegrade blood flow. The relation between normal coronary artery blood flow and mortality after myocardial infarction is well documented. A meta-analysis of angiographic infarct trials showed normal flow was associated with a mortality of 3.7% compared with 6.6% (P = 0.0001) in patients with impaired flow and 9.2% (P = 0.0003) in patients with occluded or nearly occluded infarct related arteries.1 This relation extends to microvascular reperfusion so that mortality after myocardial infarction can be reduced to less than 1% if normal epicardial blood flow and myocardial perfusion are restored.2 The mortality benefits of restoring normal flow have been shown to extend up to 12 years.3 Early restoration of normal myocardial blood flow must therefore be the therapeutic goal of the management of acute myocardial infarction.

    Angioplasty is more widely applicable

    For the past 20 years there have been two methods for restoring blood flow. Thrombolysis (the current first line treatment) is pharmacological, can be applied to only 60-80% …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular